Abstract
We have previously shown that the binding site for GTPase activating protein of Ras (RasGAP) in the PDGF β-receptor, Tyr771, is phosphorylated to a much lower extent in the heterodimeric configuration of PDGF α- and β-receptors, compared to the PDGF β-receptor homodimer. The decreased recruitment of the RasGAP to the receptor leads to prolonged activation of the Ras/MAP kinase pathway, which could explain the increase in mitogenicity seen upon induction of heterodimers. The molecular mechanism underlying these differences was investigated. We could show that the loss of phosphorylation of Tyr771 was dependent on presence of intact binding sites for the protein tyrosine phosphatase SHP-2 on the PDGF β-receptor. Thus, in PDGF receptor mutants in which binding of SHP-2 was lost, a higher degree of phosphorylation of Tyr771 was seen, while other phosphorylation sites in the receptor remained virtually unaffected. Thus, SHP-2 appears to play an important role in modulating phosphorylation of Y771, thereby controlling RasGAP recruitment and Ras/MAP kinase signaling in the heterodimeric configuration of the PDGF receptors.
Similar content being viewed by others
References
Andrews DM, Kitchin J, Seale PW . 1991 Int. J. Pept. Protein Res. 38: 469–475
Bazenet CE, Kazlauskas A . 1994 Oncogene 9: 517–525
Bennett AM, Hausdorff SF, O'Reilly AM, Freeman RM, Neel BG . 1996 Mol. Cell. Biol. 16: 1189–1202
Bergsten E, Uutela M, Li X, Pietras K, Östman A, Heldin CH, Alitalo K, Eriksson U . 2001 Nat. Cell Biol. 3: 512–516
Claesson-Welsh L, Eriksson A, Morén A, Severinsson L, Ek B, Östman A, Betsholtz C, Heldin CH . 1988 Mol. Cell. Biol. 8: 3476–3486
Claesson-Welsh L, Eriksson A, Westermark B, Heldin CH . 1989 Proc. Natl. Acad. Sci. USA 86: 4917–4921
Cleghon V, Feldmann P, Ghiglione C, Copeland TD, Perrimon N, Hughes DA, Morrison DK . 1998 Mol. Cell 2: 719–727
Ekman S, Thuresson ER, Heldin CH, Rönnstrand L . 1999 Oncogene 18: 2481–2488
Gilbertson DG, Duff ME, West JW, Kelly JD, Sheppard PO, Hofstrand PD, Gao Z, Shoemaker K, Bukowski TR, Moore M, Feldhaus AL, Humes JM, Palmer TE, Hart CE . 2001 J. Biol. Chem. 276: 27406–27414
Heidaran MA, Beeler JF, Yu JC, Ishibashi T, LaRochelle WJ, Pierce JH, Aaronson SA . 1993 J. Biol. Chem. 268: 9287–9295
Heidaran MA, Pierce JH, Lombardi D, Ruggiero M, Gutkind JS, Matsui T, Aaronson SA . 1991 Mol. Cell. Biol. 11: 134–142
Heldin CH, Östman A, Rönnstrand L . 1998 Biochim. Biophys. Acta 1378: F79–F113
Kazlauskas A, Feng GS, Pawson T, Valius M . 1993 Proc. Natl. Acad. Sci. USA 90: 6939–6943
Klinghoffer RA, Kazlauskas A . 1995 J. Biol. Chem. 270: 22208–22217
LaRochelle WJ, Jeffers M, McDonald WF, Chillakuru RA, Giese NA, Lokker NA, Sullivan C, Boldog FL, Yang M, Vernet C, Burgess CE, Fernandes E, Deegler LL, Rittman B, Shimkets J, Shimkets RA, Rothberg JM, Lichenstein HS . 2001 Nat. Cell Biol. 3: 517–521
Li W, Nishimura R, Kashishian A, Batzer AG, Kim WJ, Cooper JA, Schlessinger J . 1994 Mol. Cell Biol. 14: 509–517
Li X, Pontén A, Aase K, Karlsson L, Abramsson A, Uutela M, Bäckström G, Hellström M, Boström H, Li H, Soriano P, Betsholtz C, Heldin CH, Alitalo K, Östman A, Eriksson U . 2000 Nat. Cell Biol. 2: 302–309
Morgenstern JP, Land H . 1990 Nucleic Acids Res. 18: 1068–
Mori S, Rönnstrand L, Yokote K, Engström A, Courtneidge SA, Claesson-Welsh L, Heldin CH . 1993 EMBO J. 12: 2257–2264
Pawson T, Nash P . 2000 Genes Dev. 14: 1027–1047
Rivard N, McKenzie FR, Brondello JM, Pouyssegur J . 1995 J. Biol. Chem. 270: 11017–11024
Roche S, McGlade J, Jones M, Gish GD, Pawson T, Courtneidge SA . 1996 EMBO J. 15: 4940–4948
Rönnstrand L, Arvidsson AK, Kallin A, Rorsman C, Hellman U, Engström U, Wernstedt C, Heldin CH . 1999 Oncogene 18: 3696–3702
Rönnstrand L, Mori S, Arvidsson AK, Eriksson A, Wernstedt C, Hellman U, Claesson-Welsh L, Heldin CH . 1992 EMBO J. 11: 3911–3919
Rupp E, Siegbahn A, Rönnstrand L, Wernstedt C, Claesson-Welsh L, Heldin CH . 1994 Eur. J. Biochem. 225: 29–41
Shi ZQ, Yu DH, Park M, Marshall M, Feng GS . 2000 Mol. Cell. Biol. 20: 1526–1536
Xiao S, Rose DW, Sasaoka T, Maegawa H, Burke Jr TR, Roller PP, Shoelson SE, Olefsky JM . 1994 J. Biol. Chem. 269: 21244–21248
Yokote K, Hellman U, Ekman S, Saito Y, Rönnstrand L, Heldin CH, Mori S . 1998 Oncogene 16: 1229–1239
Yokote K, Mori S, Siegbahn A, Rönnstrand L, Wernstedt C, Heldin CH, Claesson-Welsh L . 1996 J. Biol. Chem. 271: 5101–5111
Acknowledgements
Lars Rönnstrand holds a position as Senior Researcher funded by the Swedish Research Council.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ekman, S., Kallin, A., Engström, U. et al. SHP-2 is involved in heterodimer specific loss of phosphorylation of Tyr771 in the PDGF β-receptor. Oncogene 21, 1870–1875 (2002). https://doi.org/10.1038/sj.onc.1205210
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205210
- Springer Nature Limited
Keywords
This article is cited by
-
KRAS mutation: from undruggable to druggable in cancer
Signal Transduction and Targeted Therapy (2021)
-
Systems analysis of EGF receptor signaling dynamics with microwestern arrays
Nature Methods (2010)